Y-mabs announces priority review of bla for danyelza® (naxitamab-gqgk) in china

New york, sept. 13, 2021 (globe newswire) -- y-mabs therapeutics, inc. (“y-mabs” or the “company”), nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner sciclone pharmaceuticals (holdings) limited (“sciclone pharmaceuticals”) has been granted priority review of the biologics license application (“bla”) for danyelza® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma by the center for drug evaluation (“cde”) of china's national medical products administration (“nmpa”).
YMAB Ratings Summary
YMAB Quant Ranking